Patents Examined by Abdel A. Mohamed
  • Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
    Patent number: 7026294
    Abstract: A method for prevention of delaying the onset of diabetes using peptide antagonists of zonulin, is disclosed.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: April 11, 2006
    Assignee: University of Maryland
    Inventors: Alessio Fasano, Tammara L. Watts
  • Method and compositions for treating hyperlipidemia and other conditions
    Patent number: 7026289
    Abstract: The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: April 11, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
    Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
  • Method of protein purification
    Patent number: 7026453
    Abstract: Purification methods are provided for proteins and peptides, employing silicon carbide to bind the proteins or peptides. The methods may also be used to recover and purify recombinantly expressed proteins sequestered in inclusion bodies. The method for purifying a protein or peptide comprises contacting a solution containing the protein or peptide with silicon carbide at a binding pH for the protein or peptide to allow the protein or peptide to bind to the silicon carbide; and eluting the protein or peptide from the silicon carbide.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: April 11, 2006
    Assignee: Norgen Biotek Corporation
    Inventor: Yousef Haj-Ahmad
  • Method for increasing the serum half-life of a biologically active molecule
    Patent number: 7022673
    Abstract: A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an increased serum half-life, e.g., human urokinase plasminogen activator (human “uPA” or “hUPA”) or a fragment or derivative thereof. Pharmaceutical compositions containing such molecules and methods of using them to treat uPA-mediated and uPA receptor-mediated disorders are also provided.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: April 4, 2006
    Assignee: Chiron Corporation
    Inventors: Robert J. Drummond, Steve Rosenberg
  • Highly purified gonadotropin compositions and process for preparing them
    Patent number: 7022822
    Abstract: Purification process of humanPurification process of human urinary gonadotropins of high biological activity and chemical purity absolutely free of foreign contaminating materials derived from the use of biological reagents or chromatography dyes, from crude of gonadotropins. The high biological activity and chemically pure composition of human gonadotropins obtained by this process, are used for the treatment of infertility and are selected from the group of follitropin or menotropins, having a bioactivity greater than 2500 IU/mg protein as tested by biological assay in rats, for both FSH and LH hormones for menotropins and greater than 5000 IU/mg protein for follitropin having an FSH:LH ratio about 75:1. Pharmaceutical preparations of said gonadotropins free of these contaminating materials are also comprised within the present invention.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: April 4, 2006
    Assignee: Instituto Massone S.A.
    Inventors: Claudio Fernando Wolfenson Band, Liliana Ester Balanian, Jose-Felipe Groisman, Erundina Marta Fasanella
  • Labeled neurotensin derivatives
    Patent number: 7015306
    Abstract: Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 21, 2006
    Assignee: BioSynthema, Inc.
    Inventors: Ananthachari Srinivasan, Jack L. Erion, Michelle A. Schmidt
  • Materials for soft tissue augmentation and methods of making and using same
    Patent number: 7015198
    Abstract: Materials for soft tissue augmentation in mammals are prepared by cross-linking blood plasma proteins, preferably with a zero-length cross-linking agent. The cross-linked blood plasma proteins can be dialyzed and autoclaved. Such materials are non-antigenic, exhibit decreased allergic response, and have increased longevity with respect to proteolytic attack from natural proteases. The appearance and/or feel of soft tissue defects and/or imperfections in skin can be improved by injecting such materials into an intradermal compartment of a patient's skin.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: March 21, 2006
    Assignee: Orentreich Foundation for the Advancement of Science, Inc.
    Inventors: Norman Orentreich, Rozlyn A. Krajcik
  • Biocompatible crosslinked polymers
    Patent number: 7009034
    Abstract: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants. Visualization agents may be included with the crosslinked polymers.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: March 7, 2006
    Assignee: Incept, LLC
    Inventors: Chandrashekhar P. Pathak, Amarpreet S. Sawhney, Peter G. Edelman
  • Human appetite control by glucagon-like peptide receptor binding compounds
    Patent number: 6998387
    Abstract: A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: February 14, 2006
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Burkhard Goke, Christoph Beglinger, Thomas R. Coolidge
  • Process for producing insoluble and soluble collagen protein products from poultry skins and use thereof
    Patent number: 6995242
    Abstract: A method of extracting and fractionating collagen-rich proteinaceous materials and derivatives from poultry skin tissue and the development of the proteinaceous materials to collagen-based protein ingredients that can function as meat replacer, texturizer, binder/filler, stabilizer, or protective colloids in processed meat products. The insoluble and soluble collagen products, collagen-based protein ingredients, water-dispersible collagen-based protein ingredients are produced by heating, separating, and rapidly cooling the solid-phase below its melting temperature to exploit reformation of the helical forms which produces a high concentration of coils, a phenomenon that accounts for its ability to form cold-set thermal reversible gels and gel strength.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: February 7, 2006
    Assignee: The Lauridsen Group, Inc.
    Inventors: Ifendu Nnanna, Allen Leinen, David Hull
  • Purification method
    Patent number: 6992061
    Abstract: The invention relates to a method of removing endotoxin from preparation of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this depyrogenation step, and to the depyrogenated product and its clinical uses.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: January 31, 2006
    Assignee: National Blood Authority
    Inventors: John Edward More, Jacqueline Rott, David Roger Lewin
  • Method for restoring a fat-pad
    Patent number: 6989373
    Abstract: The present invention relates to a method for treating damaged or degenerated fat pads in a foot of a host in need thereof. The method comprises the step of injecting into the fat pad of the host a biocompatiable solution having physico-chemical and mechanical properties substantially similar to a fatty acid mixture normally present in a healthy fat pad.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: January 24, 2006
    Assignee: Bio Syntech Canada Inc.
    Inventor: Eric André DesRosiers
  • Exendins, exendin agonists, and methods for their use
    Patent number: 6989366
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: January 24, 2006
    Assignee: Amylin PHarmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar
  • Stabilized protein compositions
    Patent number: 6979442
    Abstract: This invention relates to stabilized protein compositions, methods for preparing such stabilized protein compositions, dosage forms for administering such stabilized protein compositions to mammals and methods for preventing or treating infections in mammals by administering such protein compositions to mammals. More particularly, the stabilized protein compositions of the present invention contain therapeutically effective amounts of G-CSF, such as bovine G-CSF, in combination with a stabilizing buffer, such as HEPES, TES or TRICINE, for treating and preventing infections, including mastitis, in cattle.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: December 27, 2005
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Peter C. Canning, Barbara J. Kamicker, Kasra Kasraian
  • Method of filtering viruses from a factor VIII solution
    Patent number: 6967239
    Abstract: Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filtering the solution through a hydrophilic virus filter.
    Type: Grant
    Filed: December 14, 1998
    Date of Patent: November 22, 2005
    Assignee: Laboratoire Francias du Franctionnement et des Biotechnologies
    Inventors: Abdessatar Chtourou, Michel Nogre, Pierre Porte
  • Spontaneous emulsions containing cyclosporine
    Patent number: 6960563
    Abstract: A pharmaceutical composition contains cyclosporine as the active ingredient. More specifically, the composition is an orally administered pharmaceutical formulation in the form of a spontaneous emulsion comprising cyclosporine, ethanol ethyl oleate and polyoxyethylene glycerol trioleate. A method for preparing an orally administered pharmaceutical composition involves first dissolving cyclosporine in ethanol. Polyoxyethylene glycerol trioleate and an oil component are then added, mixed and diluted in an aqueous media to form a spontaneous emulsion.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: November 1, 2005
    Assignee: Morton Grove Pharmaceuticals, Inc.
    Inventors: Kamel F. Egbaria, Michael J. Groves
  • Bioactive peptides, uses thereof and process for the production of same
    Patent number: 6958385
    Abstract: Novel bioactive peptide compositions and process for producing the same and the use of such compositions for enhancing the growth of warm blooded animals and fish is disclosed.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: October 25, 2005
    Assignee: Biotec Pharmacon ASA
    Inventors: Jan Raa, Gunnar Rorstad
  • Agents for preventing and treating thrombocytopenia
    Patent number: 6956022
    Abstract: Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: October 18, 2005
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masahiko Tamura, Yasuhiro Oda
  • Use of exendins for the reduction of food intake
    Patent number: 6956026
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: October 18, 2005
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Sunil Bhavsar
  • Isolation of neurotrophins from a mixture containing neurotrophin variants using hydrophobic interaction chromatography
    Patent number: 6953844
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: October 11, 2005
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck